An update on Idiopathic pulmonary fibrosis

Panminerva Medica

Volumn 55, Issue 2, 2013, Pages 109-120

  Margaritopoulos, G A ^a,b   Giannarakis, I ^a   Siafakas, N M ^a   Antoniou, K M ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Fibroblasts; Idiopathic pulmonary fibrosis; Pneumocytes

Indexed keywords

PIRFENIDONE; PYRIDONE DERIVATIVE;

ANIMAL; ARTICLE; DRUG EFFECT; EARLY DIAGNOSIS; FIBROSING ALVEOLITIS; HUMAN; LUNG; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR;

ANIMALS; EARLY DIAGNOSIS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRIDONES; RISK FACTORS;

EID: 84880128903     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51.
3. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9.
4. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011', 365:1079-87.
5. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42.
6. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005;128:1475-82.
7. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;1;186:88-95.
8. Tzouvelekis A, Margaritopoulos G, Loukides S, Bouros D. Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? Am J Respir Crit Care Med 2013;187:213-4.
9. Margaritopoulos GA, Romagnoli M, Poletti V, Siafakas NM, Wells AU, Antoniou KM. Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis. Eur Respir Rev 2012;1;21:48-56.
10. Thomas AQ, Lane K, Phillips J 3rd, Prince M, Markin C, Speer M et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002;165:1322-8.
11. Armanios M. Syndromes of telomere shortening. Ann Rev Genomics Hum Genet 2009;10:45-61.
12. Seibold MA, Wise AL, Speer MC, Steel MP, Brown KK, Loyd JE et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011;364:1503-12.
13. Zhang Y, Noth I, Garcia JG, Kaminski N. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med 2011;364:1576-7.
14. Pulkkinen V, Bruce S, Rintahaka J, Hodgson U, Laitinen T, Alenius H et al. ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses. FASEB J 2010;24:1167-77.
15. Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS et al. Herpes virus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003;41:2633-40.
16. Egan JJ, Stewart JP, Hasleton PS, Arrand JR, Carroll KB, Woodcock AA. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax 1995;50:1234-9.
17. Stewart JP, Egan JJ, Ross AJ, Kelly BG, Lok SS, Hasleton PS et al. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999;159:1336-41.
18. Tsukamoto K, Hayakawa H, Sato A, Chida K, Nakamura H, Miura K. Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 2000;55:958-61.
19. Lasithiotaki I, Antoniou KM, Vlahava VM, Karagiannis K, Spandidos DA, Siafakas NM et al. Detection of herpes simplex virus type-1 in patients with fibrotic lung diseases. PLoS One 2011;6:e27800.
20. Kwan M, Xu YD, Raghu G, Khalil N. Acid treatment of normal rat lungs releases transforming growth factor-betal (TGF-betal) and increases connective tissue synthesis. Proceedings of the American Thoracic Society (PATS). Am J Respir Crit Care Med 2007; A967.
21. Downing TE, Sporn TA, Bollinger RR, Davis RD, Parker W, Lin SS. Pulmonary histopathology in an experimental model of chronic aspiration is independent of acidity. Exp Biol Med (Maywood). 2008;233:1202-12.
22. Pemg DW, Chang KT, Su KC, Wu YC, Wu MT, Hsu WH et al. Exposure of airway epithelium to bile acids associated with gastroesophageal reflux symptoms: a relation to transforming growth factor-betal production and fibroblast proliferation. Chest 2007;132:1548-56.
23. Tcherakian C, Cottin V, Brillet PY, Freynet O, Naggara N, Carton Z et al. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax 2011;66:226-31.
24. Lee JS, Song JW, Wolters PJ, Elicker BM, King TE Jr, Kim DS et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012;39:352-8.
25. Samara KD, Margaritopoulos G, Wells AU, Siafakas NM, Antoniou KM. Smoking and pulmonary fibrosis: novel insights. Pulm Med 2011-, 2011:461439.
26. Katzenstein AL, Mukhopadhyay S, Zanardi C, Dexter E. Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens. Hum Pathol 2010;41:316-25.
27. Cottin V, Nunes H, Brillet PY et al. Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26:586-93.
28. Antoniou KM, Hansell DM, Rubens MB et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med 2008;177:190-4.
29. Selman M, Rojas M, Mora AL, Pardo A. Aging and interstitial lung diseases: unraveling an old forgotten player in the pathogenesis of lung fibrosis. Semin Respir Crit Care Med 2010;31:607-17.
30. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006;3:364-72.
31. Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L525-34.
32. Jayachandran A, Königshoff M, Yu H, Rupniewska E, Hecker M, Klepetko W et al. SNAI transcription factors mediate epithelialmesenchymal transition in lung fibrosis. Thorax 2009;64:1053-61.
33. Pozharskaya V, Torres-Gonzälez E, Rojas M, Gal A, Amin M, Dollard S et al. Twist: a regulator of epithelial-mesenchymal transition in lung fibrosis. PLoS One 2009;23;4:e7559.
34. Andersson-Sjöland A, de Alba CG, Nihlberg K, Becerril C, Ramirez R, Pardo A et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008;40:2129-40.
35. Antoniou KM, Papadaki HA, Soufla G, Kastrinaki MC, Damianaki A, Koutala H et al. Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in Idiopathic Pulmonary Fibrosis (IPF). Respir Med 2010;104:1535-42.
36. Maher TM, Evans IC, Bottoms SE, Mercer PF, Thorley AJ, Nicholson AG et al. Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;182:73-82.
37. Kulasekaran P, Scavone CA, Rogers DS, Arenberg DA, Thannickal VJ, Horowitz JC. Endothelin-1 and transforming growth factor-betal independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol 2009;41:484-93.
38. Cool CD, Groshong SD, Rai PR, Henson PM, Stewart JS, Brown KK. Fibroblast foci are not discrete sites of lung injury or repair: the fi broblast reticulum. Am J Respir Crit Care Med 2006;174:654-58.
39. Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sei USA 2011;108:E1475-83.
40. Patel P, West-Mays J, Kolb M, Rodrigues JC, Hoff CM, Margetts PJ. Platelet derived growth factor B and epithelial mesenchymal transition of peritoneal mesothelial cells. Matrix Biol 2010;29:97-106.
41. Nasreen N, Mohammed KA, Mubarak KK, Baz MA, Akindipe OA, Femandez-Bussy S et al. Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-betal in vitro. Am J Physiol Lung Cell Mol Physiol 2009;297:L115-24.
42. Mubarak KK, Montes-Worboys A, Regev D, Nasreen N, Mohammed KA, Faruqi I et al. Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. Eur Respir J 2012;39:133-40.
43. Chilosi M, Poletti V, Zamó A, Lestani M, Montagna L, Piccoli P et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003;162:1495-502.
44. Königshoff M, Balsara N, Pfaff EM, Kramer M, Chrobak I, Seeger W et al. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 2008:14;3:e2142.
45. Königshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 2009;119:772-87.
46. White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, Mak TW et al. Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med 2006;173:112-21.
47. Stewart GA, Hoyne GF, Ahmad SA, Jarman E, Wallace WA, Harrison DJ et al. Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes. J Pathol 2003;199:488-95.
48. Coon DR, Roberts DJ, Loscertales M, Kradin R. Differential epithelial expression of SHH and FOXF1 in usual and nonspecific interstitial pneumonia. Exp Mol Pathol 2006;80:119-23.
49. Koli K, Myllämiemi M, Vuorinen K, Salmenkivi K, Ryynänen MJ, Kinnula VL et al. Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol 2006;169:61-71.
50. Aoyagi-Ikeda K, Maeno T, Matsui H, Ueno M, Hara K, Aoki Y et al. Notch induces myofibroblast differentiation of alveolar epithelial cells via transforming growth factor-(beta}-Smad3 pathway. Am J Respir Cell Mol Biol 2011;45:136-44.
51. Kotsianidis I, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropoulos P et al. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:1121-30.
52. Hogaboam CM, Murray L, Martinez FJ. Epigenetic mechanisms through which Toll-like receptor-9 drives idiopathic pulmonary fibrosis progression. Proc Am Thorac Soc 2012;9:172-6.
53. Margaritopoulos GA, Antoniou KM, Karagiannis K, Samara KD, Lasithiotaki I, Vassalou E et al. Investigation of Toll-like receptors in the pathogenesis of fibrotic and granulomatous disorders: a bronchoalveolar lavage study. Fibrogenesis Tissue Repair 2010;11;3:20.
54. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 2008;153:S367-S78.
55. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007;35:1821-8.
56. Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995;77:493-504.
57. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996;97:232-7.
58. Chambers RC, Scotton CJ. Coagulation cascade proteinases in lung injury and fibrosis. Proc Am Thorac Soc 2012;9:96-101.
59. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transi Res 2011;157:191-9.
60. Yang S, Banerjee S, de Freitas A, Sanders YY, Ding Q, Matalon S et al. Participation of miR-200 in pulmonary fibrosis. Am J Pathol 2012;180:484-93.
61. Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma YG et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-betal-dependent and -independent mechanisms. J Immunol 2011;187:3003-14.
62. Patel AS, Lin L, Geyer A, Haspel JA, An CH, Cao J et al. Autophagy in idiopathic pulmonary fibrosis. PLoS One 2012;7:e41394.
63. Araya J, Kojima J, Takasaka N, Ito S, Fujii S, Hara H et al. Insufficient autophagy in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012 [Epub ahead of print].
64. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev' 2012;21:355-61.
65. American Thoracic Society; European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. Am J Respir Crit Care Med 2000;161:646-64.
66. Flaherty KR, King TE Jr, Raghu G, Lynch JP III, Colby TV, Travis WD et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004;170:904-10.
67. Sumikawa H, Johkoh T, Fujimoto K, Ichikado K, Colby TV, Fukuoka J et al. Usual interstitial pneumonia and nonspecific interstitial pneumonia: correlation between CT findings at the site of biopsy with pathological diagnoses. Eur J Radiol 2012;8:2919-24.
68. Taillé C, Grootenboer-Mignot S, Boursier C, Michel L, Debray MP, Fagart J et al. Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:759-66.
69. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156:684-91.
70. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
71. Travis WD, Hunninghake G, King TE Jr, Lynch DA, Colby TV, Galvin JR et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 2008;177:1338-47.
72. Kinder B W, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007;176:691-7.
73. Park IN, Jegal Y, Kim DS, Do KH, Yoo B, Shim TS et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J 2009;33:68-76.
74. Romagnoli M, Nannini C, Piciucchi S, Girelli F, Gurioli C, Casoni GL et al. Idiopathic NSIP: an Interstitial Lung Disease Associated with Autoimmune Disorders? Eur Respir J 2011;38:384-91.
75. Cottin V, Donsbeck AV, Revel D, Loire R, Cordier JF. Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. Am J Respir Crit Care Med 1998;158:1286-93.
76. Akira M, Inoue Y, Arai T, Okuma T, Kawata Y. Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia. Thorax 2011;66:61-5.
77. Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM et al.-, American Thoracic Society Committee on BAL in Interstitial Lung Disease. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185:1004-14.
78. Ohshimo S, Bonella F, Cui A, Beume M, Kohno N, Guzman J et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:1043-7.
79. Veeraraghavan S, Latsi PI, Wells AU, Pantelidis P, Nicholson AG, Colby TV et al. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 2003;22:239.
80. Tabuena RP, Nagai S, Tsutsumi T, Handa T, Minoru T, Mikuniya T et al. Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese Patients. Respiration 2005;72:490.
81. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE Jr. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008;133:226.
82. Wells AU. The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease. Eur Respir Rev 2010;19:237-41.
83. Margaritopoulos GA, Wells AU. The role of transbronchial biopsy in the diagnosis of diffuse parenchymal lung diseases: con. Rev Port Pneumol 2012;18:61-3.
84. Casoni GL, Cordeiro CR Jr, Tomassetti S, Romagnoli M, Chilosi M, Cancellieri A et al. The role of transbronchial biopsy in the diagnosis of diffuse parenchymal lung diseases: pro. Rev Port Pneumol 2012;18:57-60.
85. Katzenstein AL. Smoking-related interstitial fibrosis (SRIF), pathogenesis and treatment of usual interstitial pneumonia (UIP), and transbronchial biopsy in UIP. Mod Pathol 2012;25(Suppl 1):S68-78.
86. Babiak A, Hetzel J, Krishna G, Fritz P, Moeller P, Balli T et al. Transbronchial cryobiopsy: a new tool for lung biopsies. Respiration 2009;78:203-8.
87. Nicholson AG, Addis BJ, Bharucha H, Clelland CA, Corrin B, Gibbs AR et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004;59:500-5.
88. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001;164:1722-7.
89. Monaghan H, Wells AU, Colby TV, du Bois RM, Hansell DM, Nicholson AG. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 2004;125:522-6.
90. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040.
91. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D et al; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
92. Jiang C, Huang H, Liu J, Wang Y, Lu Z, Xu Z. Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PLoS One 2012 t[Epub ahead of print].
93. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366:1968.
94. Richeldi L. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. Eur Respir Rev 2012;21:147-51.
95. Raghu G. Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012. Lancet 2012;18;380:699-701.
96. Thabut G, Mai H, Castier Y, Groussard O, Brugiére O, Marrash-Chahla R et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003;126:469.
97. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25:745.
98. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizamy DL et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. Am J Roentgenol 1997;169:977.
99. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007;30:835-9.
100. Vancheri C. Idiopathic pulmonary fibrosis: an altered fibroblast proliferation linked to cancer biology. Proc Am Thorac Soc 2012;9:153-7.